|
Ian Hector Frazer (born 6 January 1953) is a Scottish-born Australian scientist and founding CEO and Director of Research of the Translational Research Institute (Australia).〔 (【引用サイトリンク】title= TRI Executive ) 〕 In parallel with researchers at the National Cancer Institute, Georgetown University, and University of Rochester, Frazer and his colleagues developed and patented the basic technology behind the HPV vaccine against cervical cancer, now marketed as Gardasil and Cervarix; which was the second cancer preventing vaccine, and the first vaccine designed to prevent a cancer.〔 〕〔 The Hepatitis B vaccine (HBV) protects against the development of malignant liver cancer and was the first vaccine capable of preventing the development of a specific human cancer. But, the Australia antigen was understood to be a potential vaccine seven years before the carcinogenic effect of Hepatitis B was discovered (see: ). HBV was designed to prevent the disease's other symptoms, whereas an HPV vaccine would have been low priority if HPV wasn't carcinogenic (for example, (medcompare.com ) says men are almost always clinically asymptomatic). These two viruses are the only two oncoviruses to yet have effective vaccines developed against them.〕〔 ==Biography== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ian Frazer」の詳細全文を読む スポンサード リンク
|